Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab

2020 ◽  
Vol 52 (2) ◽  
pp. 284-291 ◽  
Author(s):  
Lorenzo Bertani ◽  
Matteo Fornai ◽  
Marco Fornili ◽  
Luca Antonioli ◽  
Laura Benvenuti ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Mucosal Healing ◽  
Oncostatin M

Tu1241 SERUM ONCOSTATIN M PREDICTS MUCOSAL HEALING IN CROHN'S DISEASE PATIENTS TREATED WITH INFLIXIMAB

2020 ◽  
Vol 158 (6) ◽  
pp. S-1030
Author(s):  
Lorenzo Bertani ◽  
Luca Antonioli ◽  
Marco Fornili ◽  
Matteo Fornai ◽  
Gherardo Tapete ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Mucosal Healing ◽  
Oncostatin M

scholarly journals P454 Serum oncostatin M predicts mucosal healing in Crohn’s disease patients treated with infliximab

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S406-S406
Author(s):  
L Bertani ◽  
L Antonioli ◽  
M Fornili ◽  
M Fornai ◽  
G Tapete ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Treatment Response ◽  
Predictive Marker ◽  
Mucosal Healing ◽  
Oncostatin M ◽  
Spearman Correlation ◽  
Drug Infusion ◽  
Serum Samples ◽  
Faecal Calprotectin

Abstract Background A number of Crohn’s Disease (CD) patients fail to respond to infliximab (IFX) treatment. For this reason, the identification of a biomarker suitable to predict treatment outcome represents one of the most intriguing challenges for gastroenterologists. Oncostatin M (OSM) is a member of the interleukin 6 cytokine family, which is upregulated significantly in CD inflamed intestinal mucosa. OSM has been suggested as a promising biomarker to predict the responsiveness to anti-TNF therapy in patients with inflammatory bowel diseases. The aim of the present study was to evaluate the suitability of the evaluation of OSM serum levels as a predictive marker of treatment response to IFX. Methods We included CD patients treated with IFX during 2017 and 2018. All patients underwent a colonoscopy at week 54, when treatment response was evaluated in terms of mucosal healing (MH, defined as disappearance of ulcers). At baseline and after 14 weeks of treatment, OSM was evaluated by ELISA on serum samples collected before drug infusion. We assessed also faecal calprotectin (FC) at baseline and week 14. Mann-Whitney test was used to evaluate the correlation between OSM and FC levels at baseline and week 14 with MH at week 54. Spearman correlation between OSM and FC values at baseline and week 14 was computed as well. Logistic regression models to predict MH at week 54 were carried out by the Akaike Information Criterion (AIC) and Area Under the Curve (AUC). Results In a cohort of 45 patients (24 males) included in the study, 27 displayed MH. At baseline, OSM levels were significantly lower in treatment responders than non-responders (p < 0.001). Similar results were obtained at week 14, when FC levels also were lower in responders than non-responders (p < 0.001 for both OSM and FC). OSM values at baseline and week 14 were significantly associated (Spearman correlation = 0.92, p < 0.001). The diagnostic accuracy of binary OSM at baseline in predicting MH (AIC = 26, AUC = 0.93) was greater than that of binary FC at week 14 (AIC = 34.7, AUC = 0.89). Conclusion These preliminary data suggest that OSM and FC are able to predict the outcome of treatment with IFX. Of note, at variance with FC, the predictive capability of OSM was appreciable at baseline, thus allowing to propose OSM as a promising biomarker for driving therapeutic choices in Crohn’s disease patients.

T04.01.20 SERUM ONCOSTATIN M PREDICTS MUCOSAL HEALING IN CROHN'S DISEASE PATIENTS TREATED WITH INFLIXIMAB

2020 ◽  
Vol 52 ◽  
pp. S125-S126
Author(s):  
L. Bertani ◽  
L. Antonioli ◽  
M. Fornili ◽  
M. Fornai ◽  
G. Tapete ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Mucosal Healing ◽  
Oncostatin M

Apex Score: Predicting Flares in Small-Bowel Crohn’s Disease After Mucosal Healing

2021 ◽  
Author(s):  
Vítor Macedo Silva ◽  
Marta Freitas ◽  
Pedro Boal Carvalho ◽  
Francisca Dias de Castro ◽  
Tiago Cúrdia Gonçalves ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Small Bowel ◽  
Crohn's Disease ◽  
Mucosal Healing

P089 REAL-WORLD EXPERIENCE: CLINICAL AND ENDOSCOPIC EFFECTIVENESS OF STANDARD VEDOLIZUMAB DOSING AND MODIFIED MAINTENANCE DOSING IN PATIENTS WITH MODERATE-SEVERE CROHN’S DISEASE

2020 ◽  
Vol 26 (Supplement_1) ◽  
pp. S75-S75
Author(s):  
Scott D Lee ◽  
Anand Singla ◽  
Caitlin Kerwin ◽  
Kindra Clark-Snustad
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Adverse Events ◽  
Real World ◽  
Clinical Remission ◽  
Mucosal Healing ◽  
Clinical Disease ◽  
Endoscopic Remission ◽  
Starting Dose

Abstract Background Vedolizumab (VDZ) is an effective treatment for Crohn’s disease (CD); however, inadequate and loss of response is common. Pivotal VDZ trials evaluated alternative dosing intervals, demonstrating numeric but not statistical superiority in efficacy as compared to FDA-approved dosing. The safety and effectiveness of FDA-approved and modified-dosing schedules in a real-world population are unknown. We aimed to evaluate clinical and endoscopic effectiveness & safety of standard and modified maintenance VDZ dosing in a real world cohort. Methods We retrospectively reviewed CD patients (pts) treated with >3 months VDZ, assessing Harvey Bradshaw Index (HBI), Simple Endoscopic Score for Crohn’s disease (SESCD), Short Inflammatory Bowel Disease Questionnaire (SIBDQ), C-reactive protein (CRP), albumin and hematocrit prior to and following standard VDZ dosing, and prior to and following modified VDZ maintenance dosing. We measured duration on therapy and adverse events. Results We identified 226 eligible pts, mean age 41.5 years, 55.3% female, median disease duration 10 years, 88.9% with prior biologic exposure. Mean duration on VDZ was 28.3 months. Standard VDZ dosing: 61.5% of pts with active clinical disease and adequate follow up data achieved clinical response after 3–12 months; 41.0% had clinical remission. 51.9% of pts with active endoscopic disease and adequate follow up data achieved mucosal improvement; 42.3% had endoscopic remission; 26.0% had mucosal healing after 3–24 months. 50.0% of pts with elevated CRP and adequate follow up data normalized CRP after 3–12 months. Modified maintenance dosing: 72 non-remitters to standard VDZ dosing received modified VDZ maintenance dosing. 51.5% of pts with active clinical disease prior to starting dose modification and adequate follow up data achieved clinical response after 3–12 months of modified maintenance dosing; 42.4% had clinical remission. 22.2% of pts with SESCD ≥3 prior to starting dose modification achieved mucosal improvement after 3–24 months; 22.2% had mucosal healing. 26.7% of pts with SESCD ≥4 prior to starting modified dosing had endoscopic remission after 3–24 months. 50.0% of pts with elevated CRP and adequate follow up data normalized their CRP after 3–12 months. Safety: 82.7% of pts reported ≥1 adverse events, most commonly infection and worsening CD symptoms. Discussion Standard VDZ dosing resulted in clinical and endoscopic improvement in pts with moderate-severe CD, with prior exposure to multiple advanced therapies. For non-remitters to standard dosing, modified VDZ maintenance dosing improved clinical disease activity in ∼50% of pts and improved endoscopic disease activity in ∼20% of pts, suggesting that for pts who did not achieve remission with standard VDZ dosing, modified VDZ dosing may result in clinical and endoscopic improvement.

646 Naltrexone Therapy Improves Activity and Promotes Mucosal Healing in Active Crohn's Disease: A Placebo-Controlled Trial

2010 ◽  
Vol 138 (5) ◽  
pp. S-85-S-86 ◽  
Author(s):  
Jill P. Smith ◽  
Sandra I. Bingaman ◽  
Francesca Ruggiero ◽  
David T. Mauger ◽  
Aparna Mukherjee ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Controlled Trial ◽  
Mucosal Healing
Sign in / Sign up

Export Citation Format

Share Document